McKesson Corporation vs MINISO Group Holding Ltd — how do they compare? McKesson Corporation trades at $921.5 (market cap $106.14B), while MINISO Group Holding Ltd trades at $9.17 (market cap $2.59B). The key difference: McKesson Corporation is far larger — about 41× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.45%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and MINISO Group Holding Ltd for 24 Days on average.
| MCK | MNSO | |
|---|---|---|
Market Cap | $106.14B | $2.59B |
Volume | 794,405 | 685,013 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $22.75 |
52-Week Low | $725.17 | $8.60 |
Typical Hold Time | 74 Days | 24 Days |
Enterprise Value | $112.67B | $3.46B |
Dividend Yield | 0.41% | 7.45% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing estimates in three of the last four quarters but beating in Q1 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 5.35%. Analyst sentiment is mixed with a 60% buy rating, while recent news highlights CFO share purchases and a 52-week low.
The outlook for MNSO hinges on improving earnings consistency and margin stabilization. Investment opportunities include attractive valuation multiples like a P/E of 14.55 and P/S of 0.78, but risks involve volatile earnings, overseas margin pressures, and competitive retail dynamics. The stock's recent decline to near 52-week lows may present a value entry if operational improvements materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →